AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Bonesupport Holding

Report Publication Announcement Sep 1, 2022

3016_iss_2022-09-01_bde7310f-4738-4b11-9ad3-5895130e672b.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

BONESUPPORT's Capital Markets Day

At today's Capital Markets Day BONESUPPORT AB will provide further insight into the company's operations and strategy. The focus is the US launch of BONESUPPORT's antibiotic eluting product CERAMENT G.

BONESUPPORT's group management will, among other things, announce the following:

  • CERAMENT G has been included in the contracts with Healthtrust (approx. 1,500 hospitals) and Premier (approx. 2,500 hospitals) as of October 1, 2022.
  • Launch of the "Booster program" a focused effort to efficiently penetrate the American market with CERAMENT G.
  • Updated financial goal: 40% sales growth in the next three years (2023–2025)

The Capital Markets Day takes place today, Thursday 1 September, 14:00-16:30 at Helio, Grev Turegatan 30, in Stockholm. For physical attendance, please register here: https://financialhearings.com/event/44406

The Capital Markets Day will also be broadcast live at https://tv.streamfabriken.com /bonesupport-cmd-2022.

For more information contact:

BONESUPPORT Holding AB Emil Billbäck, CEO +46 (0) 46 286 53 70

Håkan Johansson, CFO +46 (0) 46 286 53 70 [email protected]

Cord Communications Charlotte Stjerngren +46 (0) 708 76 87 87 [email protected] www.cordcom.se

This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-09-01 08:00 CEST.

Press Release 01 September 2022 08:00:00 CEST

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport. com for more information.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

BONESUPPORT's Capital Markets Day

Talk to a Data Expert

Have a question? We'll get back to you promptly.